KalVista Pharmaceuticals (KALV) Common Equity (2014 - 2025)

KalVista Pharmaceuticals' Common Equity history runs 12 years deep, the most recent figure standing at $40.8 million for Q3 2025.

• In Q3 2025, Common Equity fell 76.39% year-over-year to $40.8 million; the TTM figure through Jul 2025 stood at $40.8 million (down 76.39% YoY), while the FY2025 annual figure was $95.4 million, down 53.82% from the prior year.
• Common Equity came in at $40.8 million for Q3 2025 at KalVista Pharmaceuticals, down from $95.4 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $257.2 million in Q2 2021 to a low of $40.8 million in Q3 2025.
• A 5-year average of $157.4 million and a median of $164.4 million in 2024 frame the typical range for Common Equity.
• Across the five-year window, Common Equity jumped 255.05% in 2022 and sank 76.39% in 2025, its largest moves.
• KalVista Pharmaceuticals' Common Equity stood at $227.5 million in 2021, then tumbled by 36.78% to $143.8 million in 2022, then retreated by 20.42% to $114.4 million in 2023, then surged by 43.61% to $164.4 million in 2024, then slumped by 75.18% to $40.8 million in 2025.
• According to Business Quant data, Common Equity over the past three periods registered $40.8 million, $95.4 million, and $164.4 million for Q3 2025, Q2 2025, and Q4 2024 respectively.

Peer Comparison